• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Carol Lynch: Addressing Misinformation About Biosimilars

Video

Carol Lynch, president of Sandoz US and head of North America, discusses which stakeholders have a role in addressing misinformation about biosimilars.

Transcript:

Who is responsible for addressing misinformation campaigns about biosimilars, and what can be done to stop them?

I think we all need to take on the task of tackling misinformation that’s out there, because I think, at best, it can lead to confusion for all stakeholders, and at worst, it can actually cause doubt about the safety and efficacy of biosimilars.

So, I think that from an FDA perspective they can definitely set out and help us with that. I think it’s on manufacturers to step up, but also the other players in the industry as well, so for example the medical societies, industry associations like [Association for Accessible Medicines] and Medicines for Europe, all play an important role in making sure that fair and balanced information is available to all stakeholders.

Recent Videos
Canavan & O’Dell
Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health.
Elena Wolff-Holz, MD.
Elena Wolff-Holz, MD, global head of clinical development at Biocon Biologics
Elena Wolff-Holz, MD
Travis Brewer, Texas Oncology
Josh Canavan, PharmD, head of pharmacy at RazorMetrics
Tiago Biachi, MD, PhD
Elie Bahou, MD, PhD
Steve Pickette, PharmD
Related Content
© 2025 MJH Life Sciences

All rights reserved.